NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Friday that its fourth quarter revenues rose 65 percent.

For the three months ended Dec. 31, CareDx reported revenues of $10.9 million, up from $6.6 million in Q4 2015, and in line with analyst estimates for revenues of $10.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.